Table 3.

Incidence rates and incidence rate ratios among patients receiving ustekinumab, etanercept, methotrexate or adalimumab

	Ustekinumab	Etanercept	Methotrexate	Adalimumab
Outcome during drug therapy
Total patient‐years	1936.56	2905.99	3650.81	6851.23
Patient‐years of follow‐up (median, p25–p75)	1.76 (0.92–2.96)	1.67 (0.69–3.20)	1.18 (0.59–2.29)	1.69 (0.84–3.07)
Number of major cardiovascular events	7	5	7	19
Incidence rate per 1000 patient‐years (95% CI)	3.61 (1.72–7.58)	1.72 (0.72–4.13)	1.92 (0.91–4.02)	2.77 (1.77–4.35)
Incidence rate ratio	1.30 (0.46–3.24)	0.62 (0.18–1.72)	0.69 (0.25–1.72)	Reference
Incidence rate ratio	1.89 (0.56–6.30)	0.90 (0.22–3.28)	Reference	1.45 (0.58–4.07)
Duration between the start of exposure to development of the outcome (years; median, p25–p75; only patients experiencing the outcome)	1.06 (0.59–1.94)	1.29 (1.08–1.82)	0.99 (0.86–1.60)	0.90 (0.46–2.29)
Outcome during drug therapy plus grace period (90 days)
Total patient‐years	2167.61	3226.03	4185.94	7632.87
Patient‐years of follow‐up (median, p25–p75)	2.01 (1.16–3.21)	1.92 (0.93–3.45)	1.43 (0.84–2.53)	1.94 (1.09–3.32)
Number of major cardiovascular events	7	6	9	23
Incidence rate per 1000 patient‐years (95% CI)	3.23 (1.54–6.77)	1.86 (0.84–4.14)	2.15 (1.12–4.13)	3.01 (2.00–4.53)
Incidence rate ratio	1.07 (0.39–2.58)	0.62 (0.21–1.56)	0.71 (0.29–1.60)	Reference
Incidence rate ratio	1.50 (0.48–4.53)	0.87 (0.25–2.72)	Reference	1.40 (0.62–3.44)
Duration between the start of exposure to development of the outcome (years; median, p25–p75; only patients experiencing the outcome)	1.06 (0.59–1.94)	1.19 (1.06–1.82)	0.99 (0.86–1.60)	0.90 (0.44–2.29)

95% CI, 95% confidence interval; p25–p75, 25th percentile‐75th percentile.